Compare Stocks

Date Range: 

 TFF PharmaceuticalsWave Life SciencesOrphazyme A/SVYNE TherapeuticsVistaGen Therapeutics
SymbolNASDAQ:TFFPNASDAQ:WVENASDAQ:ORPHNASDAQ:VYNENASDAQ:VTGN
Price Information
Current Price$9.59$6.08$5.75$3.63$2.57
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.41.81.01.51.3
Analysis Score3.53.33.03.53.5
Community Score2.82.62.12.72.9
Dividend Score0.00.00.00.00.0
Ownership Score0.02.50.00.80.0
Earnings & Valuation Score0.60.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$29.50$11.80$16.00$18.75$5.67
% Upside from Price Target207.61% upside94.08% upside178.26% upside416.53% upside120.49% upside
Trade Information
Market Cap$243.24 million$303.12 million$200.97 million$186.54 million$368.38 million
Beta2.470.35N/A0.970.52
Average Volume354,749823,14143,2761,990,3093,110,581
Sales & Book Value
Annual RevenueN/A$15.98 millionN/A$10.64 millionN/A
Price / SalesN/A18.97N/A17.53N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.50 per share$1.86 per shareN/A$2.81 per share($0.12) per share
Price / BookN/A3.27N/A1.29N/A
Profitability
Net Income$-11,870,000.00$-193,640,000.00N/A$-73,700,000.00$-20,770,000.00
EPS($5.31)($5.72)N/A($3.09)($0.50)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-1,562.01%N/AN/AN/A
Return on Equity (ROE)-59.54%-401.32%N/A-331.83%N/A
Return on Assets (ROA)-57.08%-72.82%N/A-210.68%-272.12%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.46%N/A
Current Ratio26.84%1.33%N/A4.92%0.82%
Quick Ratio26.84%1.33%N/A4.68%0.82%
Ownership Information
Institutional Ownership Percentage24.28%80.67%10.60%50.07%3.13%
Insider Ownership Percentage10.40%38.20%N/A2.20%13.67%
Miscellaneous
Employees430114110611
Shares Outstanding25.36 million49.86 million34.95 million51.39 million143.34 million
Next Earnings Date5/13/2021 (Confirmed)5/13/2021 (Confirmed)N/A8/5/2021 (Estimated)7/5/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Zacks: Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $310,000.00Zacks: Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $310,000.00
americanbankingnews.com - May 6 at 2:14 AM
 Brokerages Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $310,000.00 Brokerages Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $310,000.00
americanbankingnews.com - May 6 at 2:14 AM
Zacks: Brokerages Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Post Earnings of -$0.05 Per ShareZacks: Brokerages Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Post Earnings of -$0.05 Per Share
americanbankingnews.com - May 4 at 8:16 PM
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial OfficerVistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
finance.yahoo.com - May 4 at 1:04 PM
When is VistaGen Therapeutics Inc. (VTGN) going to be good investment?When is VistaGen Therapeutics Inc. (VTGN) going to be good investment?
marketingsentinel.com - May 3 at 12:01 PM
Looking for a Top Momentum Stock? Check Out VistaGen Therapeutics, Inc. (NASDAQ:VTGN)Looking for a Top Momentum Stock? Check Out VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
stocksregister.com - April 30 at 10:33 AM
VistaGen expands board of directorsVistaGen expands board of directors
mmm-online.com - April 29 at 6:55 PM
VistaGen Therapeutics Inc. [VTGN] gain 25.77% so far this year. What now?VistaGen Therapeutics Inc. [VTGN] gain 25.77% so far this year. What now?
dbtnews.com - April 29 at 8:54 AM
Future Outlook And Stock Price Performance For VistaGen Therapeutics, Inc. (NASDAQ:VTGN)Future Outlook And Stock Price Performance For VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
marketingsentinel.com - April 28 at 2:29 PM
Novel Anxiety and Depression Approach by VistaGen TherapeuticsNovel Anxiety and Depression Approach by VistaGen Therapeutics
finance.yahoo.com - April 27 at 2:06 PM
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of DirectorsVistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
finance.yahoo.com - April 27 at 8:21 AM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s stock falls -2.84%, but it may be worth investing inVistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s stock falls -2.84%, but it may be worth investing in
stocksregister.com - April 19 at 1:05 PM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Post Quarterly Sales of $310,000.00VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Post Quarterly Sales of $310,000.00
americanbankingnews.com - April 19 at 1:44 AM
 Brokerages Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Post Earnings of -$0.05 Per Share Brokerages Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Post Earnings of -$0.05 Per Share
americanbankingnews.com - April 17 at 8:12 PM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest UpdateVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update
americanbankingnews.com - April 16 at 1:40 AM
VistaGen Therapeutics Inc (VTGN)VistaGen Therapeutics Inc (VTGN)
investing.com - April 15 at 3:25 PM
Highlights From Day 2 Of Benzingas Biotech Small Cap ConferenceHighlights From Day 2 Of Benzinga's Biotech Small Cap Conference
benzinga.com - March 26 at 4:58 PM
VistaGen Therapeutics, Inc.’s (NASDAQ:VTGN) 1.91% gain encourages investors to the stockVistaGen Therapeutics, Inc.’s (NASDAQ:VTGN) 1.91% gain encourages investors to the stock
stocksregister.com - March 26 at 3:05 PM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Has Recovered 83.25% So Far, But Another 52.15% Gain Cannot Be Ruled OutVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Has Recovered 83.25% So Far, But Another 52.15% Gain Cannot Be Ruled Out
marketingsentinel.com - March 25 at 2:00 PM
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 ...VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 ...
apnews.com - March 23 at 4:15 AM
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive BenzodiazepinesVistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
finance.yahoo.com - March 22 at 1:11 PM
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in ...VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in ...
apnews.com - March 12 at 10:28 PM
Why Is It Moving? Analyzing The Upward Movement in VistaGen Therapeuticss Stock TodayWhy Is It Moving? Analyzing The Upward Movement in VistaGen Therapeutics's Stock Today
msn.com - March 11 at 1:54 PM
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical StudyVistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
finance.yahoo.com - March 11 at 8:42 AM
Bullish Case For VistaGen Therapeutics Is Its Pipeline Not Its Stock PriceBullish Case For VistaGen Therapeutics Is Its Pipeline Not Its Stock Price
marketbeat.com - February 22 at 1:07 PM
Will SAD Trial Make VistaGen Investors Happy?Will SAD Trial Make VistaGen Investors Happy?
nasdaq.com - February 19 at 8:19 AM
DateCompanyBrokerageAction
3/11/2021TFF PharmaceuticalsHC WainwrightBoost Price Target
3/4/2021TFF PharmaceuticalsRoth CapitalBoost Price Target
2/1/2021TFF PharmaceuticalsB. RileyReiterated Rating
11/6/2020TFF PharmaceuticalsMaxim GroupReiterated Rating
3/30/2021Wave Life SciencesTruistLower Price Target
3/30/2021Wave Life SciencesSVB LeerinkLower Price Target
3/30/2021Wave Life SciencesMizuhoLower Price Target
3/30/2021Wave Life SciencesRoyal Bank of CanadaLower Price Target
12/31/2019Wave Life SciencesSunTrust BanksReiterated Rating
12/17/2019Wave Life SciencesGuggenheimLower Price Target
12/16/2019Wave Life SciencesCowenReiterated Rating
3/30/2021Orphazyme A/SBank of AmericaDowngrade
10/2/2020VYNE TherapeuticsLifesci CapitalReiterated Rating
10/2/2020VYNE TherapeuticsNorthland SecuritiesReiterated Rating
8/6/2020VYNE TherapeuticsCi CapitalReiterated Rating
5/13/2020VYNE TherapeuticsBarclaysBoost Price Target
5/2/2019VYNE TherapeuticsCantor FitzgeraldReiterated Rating
10/9/2018VYNE TherapeuticsJefferies Financial GroupLower Price Target
1/4/2021VistaGen TherapeuticsWilliam BlairUpgrade
10/8/2020VistaGen TherapeuticsAegisInitiated Coverage
12/2/2019VistaGen TherapeuticsChardan CapitalReiterated Rating
11/4/2018VistaGen TherapeuticsOppenheimerSet Price Target
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.